Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Document Type
Journal Article
Publication Date
3-1-2019
Journal
Lancet Haematology
Volume
6
Issue
3
Inclusive Pages
e132-e143
Keywords
10.1016/S2352-3026(18)30221-7
APA Citation
Bolaños-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A., Antin, J., Arai, S., Bickett, K., Chen, Y., Damon, L., Efebera, Y., Geller, N., Giralt, S., Hari, P., Holtan, S., Horowitz, M., Jacobsohn, D., Jones, R., Liesveld, J., Logan, B., MacMillan, M., Mielcarek, M., Noel, P., Pidala, J., Porter, D., Pusic, I., Sobecks, R., Solomon, S., Weisdorf, D., Wu, J., Pasquini, M., & Koreth, J. (2019). Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).. Lancet Haematology, 6 (3). Retrieved from https://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs/2892
Peer Reviewed
1